Oncology

Coverage from the January 18, 2023, Institute for Value-Based Medicine session with Regional Cancer Care Associates held in New Brunswick, New Jersey.

Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.

A novel algorithm based on patient-reported outcome questionnaires stratified patients by disease complexity and effectively identified those at a higher risk of having an acute care visit.

The findings emphasize a need for policies that may offset the impact of direct and indirect costs for patients with breast cancer.

Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.

The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.

A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.

Colon carcinoma and acute diverticulitis have similar computed tomography imaging features that can make differential diagnosis difficult for radiologists, but a novel artificial intelligence assistance model was shown to help diagnostic accuracy.

The findings suggest that both high-risk patients and high-risk regions should be considered in clinical and policy strategies to facilitate timely breast cancer care.

Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.

A preplanned analysis of the PACIFIC-R confirms findings from the pivotal PACIFIC trial of durvalumab as consolidation therapy in unresectable NSCLC after chemoradiotherapy.

The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC).

A recent study found potential significance in PD-L1 analysis results for predicting immune treatment response in patients with advanced endometrial carcinoma.

A tool to measure chemotherapy toxicity from the Cancer and Aging Research Group can help determine emergency department visits or hospitalization risk, especially for elderly patients, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

Moving screening and prevention care more upstream can help make an impact by getting patients diagnosed with cancer earlier, said Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.

Paul Thurmes, MD, medical oncologist and hematologist, Minnesota Oncology, spoke on key responsibilities and approaches that are often lacking in cancer care.

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on how the California Cancer Care Equity Act will allow oncologists to escalate the care of patients with advanced cancers toward established centers that can better meet their needs, as well as implications from the decision to exclude genomic testing coverage in the bill.

Coverage from the New York City presentation of the Institute for Value-Based Medicine, co-chaired by Emeline Aviki, MD, MBA, of Memorial Sloan Kettering Cancer Center (MSKCC), and Robert Daly, MD, MBA, medical oncologist and lung cancer specialist at MSKCC.